Previous 10 | Next 10 |
AlloVir, Inc. (Nasdaq: ALVR), a late-clinical stage allogeneic T cell immunotherapy company, today announced that Diana Brainard, M.D., Chief Executive Officer, will participate in a fireside chat at the Piper Sandler 35 th Annual Healthcare Conference in New York City, NY on Tuesday, Novembe...
2023-11-02 11:37:32 ET More on AlloVir AlloVir: An Intriguing $3 Biotech Concern AlloVir slips after multiple insider sales AlloVir spikes as Bank of America starts at Buy on lead asset Seeking Alpha’s Quant Rating on AlloVir Historical earning...
Acushnet Holdings Corp. (GOLF) is expected to report $0.54 for Q3 2023 Paramount Global (PARA) is expected to report $0.09 for Q3 2023 Curis Inc. (CRIS) is expected to report $-2.32 for Q3 2023 Quanta Services Inc. (PWR) is expected to report $1.99 for Q3 2023 GRI Bio Inc. (GRI) i...
-- Posoleucel, a highly innovative off-the-shelf, multi-virus-specific investigational T cell therapy, continues to advance in three distinct, Phase 3, first-to-market indications in immunocompromised patients -- Enrollment in posoleucel pivotal Phase 3 multi-virus prevention, virus-assoc...
AlloVir Inc. (ALVR) is expected to report $-0.42 for Q3 2023
2023-09-21 14:44:37 ET Shares of AlloVir (NASDAQ: ALVR) fell as much as 7% early Thursday, then largely recovered to trade down around 0.7% as of 1:40 p.m. ET amid concerns over a lock-up agreement expiration for certain restricted stock units of the late clinical-stage cell therapy...
2023-09-18 13:13:33 ET For further details see: TTOO, ASTR and MBOT among mid-day movers
AlloVir, Inc. (Nasdaq: ALVR), a late-clinical stage allogeneic T cell immunotherapy company, today announced that Diana Brainard, M.D., Chief Executive Officer, will participate in the following upcoming investor conferences: Morgan Stanley 21 st Annual Global Healthcare Conference ...
2023-08-22 12:49:05 ET More on AlloVir AlloVir: 'Takes One To Know One' AlloVir: Several Late-Stage Programs Make This Worth A Look AlloVir spikes as Bank of America starts at Buy on lead asset AlloVir spikes as Gilead buys over $10M stock AlloVir gai...
2023-08-21 13:08:17 ET Gainers: Timber Pharmaceuticals ( TMBR ) +97% . China SXT Pharmaceuticals ( SXTC ) +92% . Novo Integrated Sciences ( NVOS ) +43% . Orchestra BioMed Holdings ( OBIO ) +27% . AlloVir ( ALVR ) +26% . The G...
News, Short Squeeze, Breakout and More Instantly...
AlloVir Inc. (ALVR) is expected to report $-0.16 for Q1 2024 Inter & Co. Inc. (INTR) is expected to report $0.08 for Q1 2024 Array Technologies Inc. (ARRY) is expected to report $-0.06 for Q1 2024 Sphere 3D Corp. (ANY) is expected to report $-0.23 for Q1 2024 Alpine Immune Sci...
Resideo Technologies Inc. (REZI) is expected to report $0.33 for Q1 2024 Schneider National Inc. (SNDR) is expected to report $0.13 for Q1 2024 Murphy Oil Corporation (MUR) is expected to report $0.82 for Q1 2024 Astronics Corp. - Class B (ATROB) is expected to report for Q1 2024 ...